Ranbaxy Laboratories Ltd. is a research based International pharmaceutical company with its headquarters in India. It manufactures a range of high quality, affordable generic drugs. The company has manufacturing facilities in around 9 countries. It has strong presence in around 49
countries, products available in around 125 countries globally. It has dedicated workforce of about 10,500 employees representing 51 different countries.
Ranbaxy was established in 1961 and went public in the year 1973. It has global sales of US $1340 million for the year ended on 31st December, 2006. It has the largest market in USA (sales appx. US $380 million); then come Europe and BRICS (Brazil, Russia, India, China, South Africa).
Ranbaxy has a strong R&D competence that provides a sustainable competitive advantage to the company. It has scholarly pool of about 1100 scientists, engaged in out-of-box researches. Ranbaxy spends over 7% of its sales on R&D. Licensing of once-a-day Ciprofloxacin formulation, using NDDS (Novel Drug Delivery System) on a worldwide basis, was the first international success for the company.
Ranbaxy is focused on Discovery and development of drugs on anti-infectives, urology, respiratory/ inflammatory and metabolic diseases.
Top ten molecules of the company are:
- Cefpodoxime Proxetil
- Ketorolac Tromethamine
Plot 90, Sector 32,
Gurgaon -122001 (Haryana), INDIA
Web site: www.ranbaxy.com
Quarterly Results of Ranbaxy
|Dec 2006(3 rd quarter)||Sept 2006(2nd quarter)||Dec 2005(3 rd quarter)|
|% Change Over Sep 2006||% Change Over Dec 2005|
Annual Results of Ranbaxy
|(12 Months)||(12 Months)||% Changes|